CPHI Worldwide 2027 will be held from November 9 to 11, 2027, at Messe Frankfurt in Frankfurt, Germany. As a professional manufacturer of high-quality natural nutritional ingredients, natural personal care ingredients, and natural APIs，Aktin Chemicals, Inc. will showcase its latest products and solutions.

AKTINPHARM^®Pharmaceutical—From Small Molecules to Complex Delivery, Bridging the Critical Path from Innovative Drug Discovery to Commercialization.

Leveraging our proprietary technology platforms  Phytopower^® Development Platform of Bioactive Molecules & Ingredients from Global Medicinal Plants, Aktinsyn^® Technology Platform of Synthetic Chemistry, and Aktinbio^® Development Platform of Biotechnology, AKTINPHARM^® offers integrated CRDMO services to global pharmaceutical enterprises, biotech companies, and Marketing Authorization Holders (MAHs). Our end-to-end capabilities span drug discovery, API process development, CMC studies, formulation development, regulatory documentation support, and commercial manufacturing.

AKTINPHARM^® focuses on natural drugs, small-molecule APIs, peptides, ADC linker-payloads, and oligonucleotide drugs/LNP delivery materials. By embedding rapid early-stage R&D, robust process development, in-depth quality studies, and seamless regulatory compliance throughout the entire product lifecycle, we empower our clients to accelerate their transformation from proof-of-concept to IND/IMPD filings and from clinical supplies to commercial manufacturing.

Small Molecules & Natural Products: From Drug Discovery to Commercial APIs.APIs

In the fields of natural drugs & small molecule APIs, AKTINPHARM^® provides comprehensive end-to-end support ranging from Hit-to-Lead & Lead discovery and optimization, route of synthesis (ROS) design, impurity profiling and structural elucidation, analytical method development and validation, to process optimization, scale-up, and cGMP-compliant commercial APIs supply. Leveraging our high-performance core scaffold libraries and extensive multi-step custom synthesis expertise, our team builds CMC pathways tailored for structural optimization, quality improvement, yield increase, cost control, and regulatory compliance to drive clinical progression and industrialization.

Peptide Therapeutics: Full-Chain Development Capabilities for Complex Modalities.

For peptide programs covering GLP-1 receptor agonists, modified peptides, complex sequence peptides, and peptide conjugates, AKTINPHARM^® offers an end-to-end R&D pipeline ranging from sample preparation, key intermediate development, synthetic route evaluation and design, impurity control, purification strategies, analytical methods development to formulation integration. In the face of critical industry challenges, such as complex sequences, difficult isomer control, significant scale-up and purification bottlenecks, stringent stability requirements, AKTINPHARM® proactively intervenes with a front-loaded CMC mindset to help our clients establish development pathways geared toward regulatory filing and scalable manufacturing from the very earliest stages.

ADC Linker-Payloads: Controlled Development and Manufacturing of Highly Potent Molecules.

In the sector of ADC linker-payloads, AKTINPHARM® focuses on the R&D and manufacturing of highly potent small molecules, natural scaffolds, cytotoxic payloads, and linker-ready intermediates. We support critical milestones ranging from payload screening, structural modification, and impurity profiling to purification scale-up and quality specification establishment. The core value of ADCs stems from targeted delivery and efficient killing, where the payload's toxicity potency, stability, available conjugation sites, and in vivo release profile directly determine its efficacy and therapeutic index. Drawing on our robust capabilities in small-molecule synthesis and quality research, AKTINPHARM^® delivers highly controlled, compliant development support for ADC linker-payloads and intermediates.

Oligonucleotide Therapeutics/LNP Delivery Materials: Crucial Enablers for RNA Therapeutics.

To support the diverse delivery requirements of oligonucleotide and RNA therapeutics—such as siRNA, ASO, and mRNA—AKTINPHARM^® has strategically expanded its portfolio into LNP functional materials (e.g., helper lipids) and other critical excipients. Represented by our Ak-HepaPur^®series, AKTINPHARM^®comprehensively addresses the multifaceted demands of oligonucleotide delivery programs, covering lipid material quality, endosomal escape efficiency, scale-up feasibility, regulatory CMC dossier integrity, and supply chain stability. We provide pivotal material support for oligonucleotide and RNA drugs, spanning early-stage formulation screening through clinical-stage development.

AKTINPHARM^®integrates discovery, process development, analytics, formulation development, regulatory support, and manufacturing into a unified technological pipeline for synchronized advancement. Through flexible FTE and FFS collaboration models, we support full-scale development needs ranging from non-GMP R&D samples to GMP clinical and commercial supply, as well as from lab-scale and pilot-scale up to commercial manufacturing, catering to our clients' differentiated demands for speed, cost and regulatory compliance at varying stages.

AKTINPHARM^® CRDMO: Making Complex Molecules More Developable, Making Advanced Therapies More Manufacturable.

In November 2027, in Frankfurt, Germany, we look forward to joining hands with you to expand global business opportunities!

If you would like to schedule a one-on-one meeting in advance, please feel free to contact us.